Top

Published in:

Open Access 01-03-2017 | Psychiatry and Preclinical Psychiatric Studies - Original Article

Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice

Published in: Journal of Neural Transmission | Issue 3/2017

Abstract

Pre-clinical and clinical studies indicated that a blockade of the NMDA receptor complex creates new opportunities for the treatment of affective disorders, including depression. The aim of the present study was to assess the influence of traxoprodil (10 mg/kg) on the activity of desipramine (10 mg/kg), paroxetine (0.5 mg/kg), milnacipran (1.25 mg/kg), and bupropion (10 mg/kg), each at sub-therapeutic doses. Moreover, brain levels of traxoprodil and tested agents were determined using HPLC. The obtained results were used to ascertain the nature of occurring interaction between traxoprodil and studied antidepressants. The experiment was carried out on naïve adult male Albino Swiss mice. Traxoprodil and other tested drugs were administered intraperitoneally. The influence of traxoprodil on the activity of selected antidepressants was evaluated in forced swim test (FST). Locomotor activity was estimated to exclude false positive/negative data. To assess the influence of traxoprodil on the concentration of used antidepressants, their levels were determined in murine brains using HPLC. Results indicated that traxoprodil potentiated activity of all antidepressants examined in FST and the observed effects were not due to the increase in locomotor activity. Only in the case of co-administration of traxoprodil and bupropion, increased bupropion concentrations in brain tissue were observed. All tested agents increased the traxoprodil levels in the brain. Administration of a sub-active dose of traxoprodil with antidepressants from different chemical groups, which act via enhancing monoaminergic transduction, caused the antidepressant-like effect in FST in mice. The interactions of traxoprodil with desipramine, paroxetine, milnacipran, and bupropion occur, at least partially, in the pharmacokinetic phase.

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354CrossRefPubMed

Biagini G, Pich EM, Carani C, Marrama P, Gustafsson JA, Fuxe K, Agnati LF (1993) Indole-pyruvic acid, a tryptophan ketoanalogue, antagonizes the endocrine but not the behavioral effects of repeated stress in a model of depression. Biol Psychiatry 33:712–719CrossRefPubMed

Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L, Raiteri M, Racagni G, Popoli M (2005) Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 25:3270–3279CrossRefPubMed

Chazot PL, Lawrence S, Thompson CL (2002) Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology 42:319–324CrossRefPubMed

Cieślik K, Klenk-Majewska B, Danilczuk Z, Wróbel A, Łupina T, Ossowska G (2007) Influence of zinc supplementation on imipramine effect in a chronic unpredictable stress (CUS) model in rats. Pharmacol Rep 59:46–52PubMed

Ciranna L (2006) Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol 4:101–114CrossRefPubMedPubMedCentral

Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133–141CrossRefPubMed

Cunha MP, Machado DG, Bettio LE, Capra JC, Rodrigues AL (2008) Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 32:1913–1920CrossRefPubMed

Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793–802CrossRefPubMedPubMedCentral

Eby GA III, Eby KL (2010) Magnesium for treatment-resistant depression: a review and hypothesis. Med Hypotheses 74:649–660CrossRefPubMed

Ghasemi M, Montaser-Kouhsari L, Shafaroodi H, Nezami BG, Ebrahimi F, Dehpour AR (2009) NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology 206:325–333CrossRefPubMed

Gogas KR (2006) Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 6:68–74CrossRefPubMed

Guscott MR, Clarke HF, Murray F, Grimwood S, Bristow LJ, Hutson PH (2003) The effect of (±)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur J Pharmacol 476:193–199CrossRefPubMed

Hashimoto K (2011) The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 35:1558–1568CrossRefPubMed

Iversen L (2005) The monoamine hypothesis of depression. In: Licino J, Wong ML (eds) Biology of depression. From novel insights to therapeutic strategies. Viley-VCH Verlag, Weinheim, pp 76–81

Johnson K, Shah A, Jaw-Tsai S, Baxter J, Prakash C (2003) Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-d-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers. Drug Metab Dispos 31:76–87CrossRefPubMed

Keck PE Jr, Hsu HA, Papadakis K, Russo J Jr (2009) Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol 32:199–204CrossRefPubMed

Kew JN, Trube G, Kemp JA (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol 497:761–772CrossRefPubMedPubMedCentral

Kohno T, Kimura M, Sasaki M, Obata H, Amaya F, Saito S (2012) Milnacipran inhibits glutamatergic N-methyl-d-aspartate receptor activity in spinal dorsal horn neurons. Mol Pain 8:45CrossRefPubMedPubMedCentral

Maj J, Rogóż Z, Skuza G (1992a) The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats. Pol J Pharmacol Pharm 44:217–226PubMed

Maj J, Rogóż Z, Skuza G, Sowińska H (1992b) The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test. Pol J Pharmacol Pharm 44:337–346CrossRefPubMed

Martin P, Waters N, Waters S, Carlsson A, Carlsson ML (1997) MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur J Pharmacol 335:107–116CrossRefPubMed

Menniti F, Chenard B, Collins M, Ducat M, Shalaby I, White F (1997) CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur J Pharmacol 331:117–126CrossRefPubMed

Michael-Titus AT, Bains S, Jeetle J, Whelpton R (2000) Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex—a possible mechanism of neuroprotection in major depression? Neuroscience 100:681–684CrossRefPubMed

Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 157:1301–1317CrossRefPubMedPubMedCentral

Nowak G, Ordway GA, Paul IA (1995) Alterations in the N-methyl-d-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 675:157–164CrossRefPubMed

Nowak G, Siwek M, Dudek D, Zięba A, Pilc A (2003) Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol 55:1143–1147CrossRefPubMed

Peng WH, Lo KL, Lee YH, Hung TH, Lin YC (2007) Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice. Life Sci 81:933–938CrossRefPubMed

Permoda-Osip A, Rybakowski J (2011) Glutamatergic conception of mood disorders. Psychiatr Pol 45:875–888PubMed

Piotrowska A, Siwek A, Wolak M, Pochwat B, Szewczyk B, Opoka W, Poleszak E, Nowak G (2013) Involvement of the monoaminergic system in the antidepressant-like activity of chromium chloride in the forced swim test. J Physiol Pharmacol 64:493–498PubMed

Pittaluga A, Raiteri L, Longordo F, Luccini E, Barbiero VS, Racagni G, Popoli M, Raiteri M (2007) Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 53:27–36CrossRefPubMed

Poleszak E, Wlaź P, Kędzierska E, Radziwon-Zaleska M, Pilc A, Fidecka S, Nowak G (2005) Effects of acute and chronic treatment with magnesium in the forced swim test in rats. Pharmacol Rep 57:654–658PubMed

Poleszak E, Wlaź P, Szewczyk B, Wlaź A, Kasperek R, Wróbel A, Nowak G (2011) A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm 118:1535–1546CrossRefPubMedPubMedCentral

Poleszak E, Wośko S, Serefko A, Szopa A, Wlaź A, Szewczyk B, Nowak G, Wlaź P (2013) Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice. Prog Neuropsychopharmacol Biol Psychiatry 46:29–35CrossRefPubMed

Poleszak E, Wośko S, Serefko A, Wlaź A, Kasperek R, Dudka J, Wróbel A, Nowak G, Wlaź P (2014) The effects of ifenprodil on the activity of antidepressant drugs in the forced swim test in mice. Pharmacol Rep 66:1031–1036CrossRefPubMed

Poleszak E, Szopa A, Wyska E, Wośko S, Serefko A, Wlaź A, Pieróg M, Wróbel A, Wlaź P (2015) The influence of caffeine on the activity of moclobemide, venlafaxine, bupropion and milnacipran in the forced swim test in mice. Life Sci 136:13–18CrossRefPubMed

Poleszak E, Stasiuk W, Szopa A, Wyska E, Serefko A, Oniszczuk A, Wośko S, Świąder K, Wlaź P (2016) Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. Metab Brain Dis 31:803–814CrossRefPubMedPubMedCentral

Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336PubMed

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631–637CrossRefPubMed

Pużynski S (2005) Methodologic problems of clinical investigations of antidepressants. Psychiatr Pol 39:435–447PubMed

Randrup A, Braestrup C (1977) Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology 53:309–314CrossRefPubMed

Rogóż Z (2009) Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats. Pharmacol Rep 61:1173–1178CrossRefPubMed

Rogóż Z, Skuza G, Maj J, Danysz W (2002) Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 42:1024–1030CrossRefPubMed

Rogóż Z, Skuza G, Kuśmider M, Wójcikowski J, Kot M, Daniel WA (2004) Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol 56:179–185PubMed

Sennfelt DA, Marques da Silva MA, Tavares AP (2011) Bupropion in the treatment of major depressive disorder in real-life practice. Clin Drug Investig 31(Suppl 1):19–24CrossRefPubMed

Siwek M, Dudek D, Paul IA, Sowa-Kućma M, Zięba A, Popik P, Pilc A, Nowak G (2009) Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord 118:187–195CrossRefPubMed

Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R (1996) Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29:23–26CrossRefPubMed

Sproule BA, Naranjo CA, Brenmer KE, Hassan PC (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 33:454–471CrossRefPubMed

Stasiuk W, Serefko A, Szopa A, Wyska E, Świąder K, Wlaź P, Poleszak E (2016) Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice. Pharmacol Rep 68:960–963CrossRefPubMed

Szewczyk B, Brański P, Wierońska JM, Pałucha A, Pilc A, Nowak G (2002) Interaction of zinc with antidepressants in the forced swimming test in mice. Pol J Pharmacol 54:681–685CrossRefPubMed

Szewczyk B, Poleszak E, Wlaź P, Wróbel A, Blicharska E, Cichy A, Dybała M, Siwek A, Pomierny-Chamioło L, Piotrowska A, Brański P, Pilc A, Nowak G (2009) The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry 33:323–329CrossRefPubMed

Szewczyk B, Pałucha-Poniewiera A, Poleszak E, Pilc A, Nowak G (2012) Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs 21:91–102CrossRefPubMed

Szopa A, Poleszak E, Wyska E, Serefko A, Wośko S, Wlaź A, Pieróg M, Wróbel A, Wlaź P (2016) Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice. Naunyn Schmiedebergs Arch Pharmacol 389:211–221CrossRefPubMed

Tran PV, Bymaster FP, McNamara RK, Potter WZ (2003) Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 23:78–86CrossRefPubMed

Wilkes S (2006) Bupropion. Drugs Today (Barc) 42:671–681CrossRef

Willetts J, Balster RL, Leander JD (1990) The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423–428CrossRefPubMed

Wlaź P, Kasperek R, Wlaź A, Szumiło M, Wróbel A, Nowak G, Poleszak E (2011) NMDA and AMPA receptors are involved in the antidepressant-like activity of tianeptine in the forced swim test in mice. Pharmacol Rep 63:1526–1532CrossRefPubMed

Wolak M, Siwek A, Szewczyk B, Poleszak E, Pilc A, Popik P, Nowak G (2013) Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test. Pharmacol Rep 65:991–997CrossRefPubMed

Wolosker H (2007) NMDA receptor regulation by d-serine: new findings and perspectives. Mol Neurobiol 36:152–164CrossRefPubMed

Yan QS, Reith ME, Jobe PC, Dailey JW (1997) Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 765:149–158CrossRefPubMed

Zarate CA Jr, Singh JB, Quiroz JA, De JG, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS (2006) A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163:153–155CrossRefPubMed

Title: Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice
Publication date: 01-03-2017
Published in: Journal of Neural Transmission / Issue 3/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-016-1657-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Regulation of emotion in ADHD: can children with ADHD override the natural tendency to approach positive and avoid negative pictures?

Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome

The differential relationship between trait anxiety, depression, and resting frontal α-asymmetry

Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson’s disease

Motion and emotion: anxiety–axial connections in Parkinson’s disease

Brain structural profile of multiple system atrophy patients with cognitive impairment